BRIEF-Inhibrx Biosciences Reports Positive Topline Results From Its Registrational Trial Of Ozekibart (Inbrx-109) In Chondrosarcoma And Provides Updates On Colorectal Cancer And Ewing Sarcoma Expansion Cohorts

Reuters

Oct 24

BRIEF-<a href="https://laohu8.com/S/INBX">Inhibrx Biosciences</a> Reports Positive Topline Results From Its Registrational Trial Of Ozekibart (Inbrx-109) In Chondrosarcoma And Provides Updates On Colorectal Cancer And Ewing Sarcoma Expansion Cohorts

Oct 24 (Reuters) - Inhibrx Biosciences Inc INBX.O:

INHIBRX BIOSCIENCES REPORTS POSITIVE TOPLINE RESULTS FROM ITS REGISTRATIONAL TRIAL OF OZEKIBART (INBRX-109) IN CHONDROSARCOMA AND PROVIDES UPDATES ON COLORECTAL CANCER AND EWING SARCOMA EXPANSION COHORTS
INHIBRX BIOSCIENCES INC - OZEKIBART MEETS PRIMARY ENDPOINT IN CHONDROSARCOMA
INHIBRX BIOSCIENCES INC - PLANS TO FILE BLA IN Q2 2026
INHIBRX BIOSCIENCES INC - OZEKIBART REDUCES RISK OF DISEASE PROGRESSION BY 52%
INHIBRX BIOSCIENCES INC - 23% RESPONSE RATE AND 92% DISEASE CONTROL RATE

Source text: ID:nPn4NYYlna

Further company coverage: INBX.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2577530961"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2577530961\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2577530961?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-24 06:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2577530961","market":"fut","top_or_hot":-1,"title":"BRIEF-Inhibrx Biosciences Reports Positive Topline Results From Its Registrational Trial Of Ozekibart (Inbrx-109) In Chondrosarcoma And Provides Updates On Colorectal Cancer And Ewing Sarcoma Expansion Cohorts","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/INBX\">Inhibrx Biosciences</a> Reports Positive Topline Results From Its Registrational Trial Of Ozekibart (Inbrx-109) In Chondrosarcoma And Provides Updates On Colorectal Cancer And Ewing Sarcoma Expansion Cohorts</title></head><body><p><span>Oct 24 (Reuters)</span><span> - </span>Inhibrx Biosciences Inc <span>INBX.O</span>:</p><ul><li><p>INHIBRX BIOSCIENCES REPORTS POSITIVE TOPLINE RESULTS FROM ITS REGISTRATIONAL TRIAL OF OZEKIBART (INBRX-109) IN CHONDROSARCOMA AND PROVIDES UPDATES ON COLORECTAL CANCER AND EWING SARCOMA EXPANSION COHORTS</p></li><li><p>INHIBRX BIOSCIENCES INC - OZEKIBART MEETS PRIMARY ENDPOINT IN CHONDROSARCOMA</p></li><li><p>INHIBRX BIOSCIENCES INC - PLANS TO FILE BLA IN <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026</p></li><li><p>INHIBRX BIOSCIENCES INC - OZEKIBART REDUCES RISK OF DISEASE PROGRESSION BY 52%</p></li><li><p>INHIBRX BIOSCIENCES INC - 23% RESPONSE RATE AND 92% DISEASE CONTROL RATE</p></li></ul><p>Source text: <span>ID:nPn4NYYlna</span></p><p>Further company coverage: <span>INBX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Inhibrx Biosciences Reports Positive Topline Results From Its Registrational Trial Of Ozekibart (Inbrx-109) In Chondrosarcoma And Provides Updates On Colorectal Cancer And Ewing Sarcoma Expansion Cohorts</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Inhibrx Biosciences Reports Positive Topline Results From Its Registrational Trial Of Ozekibart (Inbrx-109) In Chondrosarcoma And Provides Updates On Colorectal Cancer And Ewing Sarcoma Expansion Cohorts\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-24 06:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/INBX\">Inhibrx Biosciences</a> Reports Positive Topline Results From Its Registrational Trial Of Ozekibart (Inbrx-109) In Chondrosarcoma And Provides Updates On Colorectal Cancer And Ewing Sarcoma Expansion Cohorts</title></head><body><p><span>Oct 24 (Reuters)</span><span> - </span>Inhibrx Biosciences Inc <span>INBX.O</span>:</p><ul><li><p>INHIBRX BIOSCIENCES REPORTS POSITIVE TOPLINE RESULTS FROM ITS REGISTRATIONAL TRIAL OF OZEKIBART (INBRX-109) IN CHONDROSARCOMA AND PROVIDES UPDATES ON COLORECTAL CANCER AND EWING SARCOMA EXPANSION COHORTS</p></li><li><p>INHIBRX BIOSCIENCES INC - OZEKIBART MEETS PRIMARY ENDPOINT IN CHONDROSARCOMA</p></li><li><p>INHIBRX BIOSCIENCES INC - PLANS TO FILE BLA IN <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026</p></li><li><p>INHIBRX BIOSCIENCES INC - OZEKIBART REDUCES RISK OF DISEASE PROGRESSION BY 52%</p></li><li><p>INHIBRX BIOSCIENCES INC - 23% RESPONSE RATE AND 92% DISEASE CONTROL RATE</p></li></ul><p>Source text: <span>ID:nPn4NYYlna</span></p><p>Further company coverage: <span>INBX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INBX","symbol_name":"Inhibrx Biosciences","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251023:nTUA8V0T2Z:1","article_id":"2577530961","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2577530961","pubTimestamp":1761259340,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Inhibrx Biosciences Reports Positive Topline Results From Its Registrational Trial Of Ozekibart (Inbrx-109) In Chondrosarcoma And Provides Updates On Colorectal Cancer And Ewing Sarcoma Expansio","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"INBX":"Inhibrx Biosciences","BK4139":"生物科技"},"translate_title":"简介-Inhibrx Biosciences报告了其Ozekibart(Inbrx-109)在软骨肉瘤中的注册试验的积极顶线结果，并提供了结直肠癌和尤文肉瘤扩展队列的最新情况","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INBX":0.9},"content_text":"BRIEF-Inhibrx Biosciences Reports Positive Topline Results From Its Registrational Trial Of Ozekibart (Inbrx-109) In Chondrosarcoma And Provides Updates On Colorectal Cancer And Ewing Sarcoma Expansion CohortsOct 24 (Reuters) - Inhibrx Biosciences Inc INBX.O:INHIBRX BIOSCIENCES REPORTS POSITIVE TOPLINE RESULTS FROM ITS REGISTRATIONAL TRIAL OF OZEKIBART (INBRX-109) IN CHONDROSARCOMA AND PROVIDES UPDATES ON COLORECTAL CANCER AND EWING SARCOMA EXPANSION COHORTSINHIBRX BIOSCIENCES INC - OZEKIBART MEETS PRIMARY ENDPOINT IN CHONDROSARCOMAINHIBRX BIOSCIENCES INC - PLANS TO FILE BLA IN Q2 2026INHIBRX BIOSCIENCES INC - OZEKIBART REDUCES RISK OF DISEASE PROGRESSION BY 52%INHIBRX BIOSCIENCES INC - 23% RESPONSE RATE AND 92% DISEASE CONTROL RATESource text: ID:nPn4NYYlnaFurther company coverage: INBX.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}